HRP20130869T1 - 5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola - Google Patents
5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola Download PDFInfo
- Publication number
- HRP20130869T1 HRP20130869T1 HRP20130869AT HRP20130869T HRP20130869T1 HR P20130869 T1 HRP20130869 T1 HR P20130869T1 HR P20130869A T HRP20130869A T HR P20130869AT HR P20130869 T HRP20130869 T HR P20130869T HR P20130869 T1 HRP20130869 T1 HR P20130869T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- prophylaxis
- treatment
- medicine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170097 | 2009-09-11 | ||
| PCT/EP2010/063136 WO2011029827A1 (en) | 2009-09-11 | 2010-09-08 | 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130869T1 true HRP20130869T1 (hr) | 2013-10-25 |
Family
ID=42830122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130869AT HRP20130869T1 (hr) | 2009-09-11 | 2010-09-08 | 5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola |
Country Status (34)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) * | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| CN101155781B (zh) * | 2005-04-06 | 2012-11-07 | 霍夫曼-拉罗奇有限公司 | 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物 |
| CA2664119A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en not_active Ceased
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 HR HRP20130869AT patent/HRP20130869T1/hr unknown
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active Active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 RS RS20130395A patent/RS52987B/sr unknown
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130869T1 (hr) | 5-(3,4-dikloro-fenil)-n-(2-hidroksi-cikloheksil)-6-(2,2,2-trifluoro-etoksi)-nikotinamid i njegove soli kao sredstva za poveä†anje hdl-kolesterola | |
| US11833156B2 (en) | Heterocyclic compounds as pad inhibitors | |
| CA2898631C (en) | Toxic aldehyde related diseases and treatment | |
| HRP20160334T1 (hr) | Pirano [3, 2 - d][1, 3]tiazol kao inhibitori glikozidaze | |
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| WO2006124490A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| HRP20190857T1 (hr) | Inhibitori glikozidaze | |
| AU2008247483A1 (en) | Intravenous and oral dosing of a direct-acting and reversible P2Y12 inhibitor | |
| HRP20160370T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini i njihova uporaba | |
| WO2018165718A1 (en) | Heterocyclic inhibitors of pcsk9 | |
| WO2017015360A1 (en) | Quinolone-3-diarylethers | |
| WO2018049328A1 (en) | Bicyclic compounds useful as gpr120 modulators | |
| WO2014025942A1 (en) | Nmda receptor modulators and uses related thereto | |
| EP1080083A1 (de) | Neue heterocyclisch substituierte amide mit cystein-protease hemmender wirkung | |
| DK1513519T3 (da) | Anvendelse af substituerede cyanopyrrolidiner til behandling af hyperlipidæmi | |
| WO2006085113A3 (en) | 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists | |
| EP3475260B1 (en) | Compounds for use as an anti-bacterial or anti-fungal agent and as a zinc sensor | |
| Hamaguchi et al. | Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436 | |
| Singh et al. | Design and Synthesis of some Novel oxazole derivatives and their biomedicinal efficacy. | |
| RU2020113185A (ru) | Композиции солей сульфасалазина и способы их применения | |
| CN101981009B (zh) | 作为hdl-胆固醇升高剂的2-三氟甲基烟酰胺衍生物 | |
| CN113501826B (zh) | 作为tdp2的抑制剂的呋喃并喹啉二酮 | |
| EP1694657A1 (en) | Compositions comprising an hiv protease inhibitor | |
| HRP20150583T1 (hr) | Derivati kinolina, farmaceutski sastavi koji ih sadrže i njihova uporaba | |
| KR20150093796A (ko) | 피리돈 유도체 및 결핵의 치료에서의 그의 용도 |